文献速递眼底病与葡萄膜炎

二甲双胍与2型糖尿病患者年龄相关性黄斑变性风险:一项回顾性队列研究

Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study.
PubMed 文献 · Br J Ophthalmol · 2022-02-03

该研究基于英国IQVIA医学研究数据(1995-2019)开展大规模人群回顾性开放队列研究,纳入173 689例≥40岁、有新发2型糖尿病且记录有一种或以上降糖药的患者,比较使用二甲双胍(伴或不伴其他降糖药)与仅使用其他降糖药者新诊断年龄相关性黄斑变性(AMD)的风险。中位随访4.8年,3111例(1.8%)发生AMD,调整后HR为1.02(95%CI 0.92-1.12),未发现二甲双胍与AMD风险相关的证据。

要点

  • 在需治疗的2型糖尿病初级保健患者中,未发现二甲双胍使用与AMD风险相关。
  • 二甲双胍组(伴或不伴其他降糖药)与仅用其他降糖药组相比,AMD诊断的调整HR为1.02(95%CI 0.92-1.12)。
  • 研究采用时间依赖暴露设计,暴露状态按3个月间隔更新。

核心结论

  • 未发现二甲双胍与需治疗的2型糖尿病初级保健患者AMD风险相关的证据。

研究设计与样本

  • 基于英国IQVIA医学研究数据(1995-2019)的大规模人群回顾性开放队列研究,采用时间依赖暴露设计。
  • 纳入173 689例年龄≥40岁、诊断为2型糖尿病且有至少一种降糖药记录的患者,57%为男性,平均(SD)年龄62.8(11.6)岁。
  • 暴露组为处方二甲双胍(伴或不伴其他降糖药)者,对照组为仅处方其他降糖药者,暴露状态按3个月间隔更新。
  • 采用扩展Cox比例风险回归计算新诊断AMD的调整HR。

主要发现

  • 中位随访4.8年(IQR 2.3-8.3,范围0.5-23.8),3111例(1.8%)患者发生AMD。
  • 与仅使用其他降糖药者相比,使用二甲双胍(伴或不伴其他降糖药)者AMD诊断的调整HR为1.02(95%CI 0.92-1.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Age-related macular degeneration (AMD) in its late stages is a leading cause of sight loss in developed countries. Some previous studies have suggested that metformin may be associated with a reduced risk of developing AMD, but the evidence is inconclusive. AIMS: To explore the relationship between metformin use and development of AMD among patients with type 2 diabetes in the UK. METHODS: A large, population-based retrospective open cohort study with a time-dependent exposure design was carried out using IQVIA Medical Research Data, 1995-2019. Patients aged ≥40 with diagnosed type 2 diabetes were included.The exposed group was those prescribed metformin (with or without any other antidiabetic medications); the comparator (unexposed) group was those prescribed other antidiabetic medications only. The exposure status was treated as time varying, collected at 3-monthly time intervals.Extended Cox proportional hazards regression was used to calculate the adjusted HRs for development of the outcome, newly diagnosed AMD. RESULTS: A total of 173 689 patients, 57% men, mean (SD) age 62.8 (11.6) years, with incident type 2 diabetes and a record of one or more antidiabetic medications were included in the study. Median follow-up was 4.8 (IQR 2.3-8.3, range 0.5-23.8) years. 3111 (1.8%) patients developed AMD. The adjusted HR for diagnosis of AMD was 1.02 (95% CI 0.92 to 1.12) in patients prescribed metformin (with or without other antidiabetic medications) compared with those prescribed any other antidiabetic medication only. CONCLUSION: We found no evidence that metformin was associated with risk of AMD in primary care patients requiring treatment for type 2 diabetes.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Gokhale KM, Adderley NJ, Subramanian A, et al. Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study. Br J Ophthalmol. 2022. PMID: 35115301. doi:10.1136/bjophthalmol-2021-319641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。